Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 372Neoplasms 325Neoplasm Metastasis 288Leukemia, Myeloid, Acute 280Breast Neoplasms 272Colorectal Neoplasms 239Melanoma 193Ovarian Neoplasms 190Recurrence 184Multiple Myeloma 178Prostatic Neoplasms 158Lung Neoplasms 158Pancreatic Neoplasms 151Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 147Glioblastoma 146Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 115Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 109Brain Neoplasms 105Advanced Solid Tumors 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 102Lymphoma 102Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Lymphoma, Follicular 92Endometrial Neoplasms 92

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Hormone Refractory Prostate Cancer × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡